Using PSMA imaging for prognostication in localized and advanced prostate cancer

MJ Roberts, T Maurer, M Perera, M Eiber… - Nature Reviews …, 2023 - nature.com
The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, helping to …

Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer

O Sartor, J De Bono, KN Chi, K Fizazi… - … England Journal of …, 2021 - Mass Medical Soc
Background Metastatic castration-resistant prostate cancer remains fatal despite recent
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …

The Evolving Role of 18F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer

K Shen, B Liu, X Zhou, Y Ji, L Chen, Q Wang… - Frontiers in …, 2021 - frontiersin.org
Positron emission tomography/computed tomography (PET/CT) is widely used in prostate
cancer to evaluate the localized tumor burden and detect symptomatic metastatic lesions …

Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 …

PH Kuo, MJ Morris, J Hesterman, AT Kendi, K Rahbar… - Radiology, 2024 - pubs.rsna.org
Background Lutetium 177 [177Lu] Lu-PSMA-617 (177Lu-PSMA-617) is a prostate-specific
membrane antigen (PSMA)–targeted radioligand therapy for metastatic castration-resistant …

Stereotactic radiotherapy for lesions detected via 68Ga-prostate-specific membrane antigen and 18F-fluorodexyglucose positron emission tomography/computed …

J Pan, Y Wei, T Zhang, C Liu, X Hu, J Zhao… - European Urology …, 2022 - Elsevier
Background Dual-tracer positron emission tomography/computed tomography (PET/CT) with
a 68 Ga-labelled prostate-specific membrane antigen (PSMA) ligand and 18 F …

The current landscape of prostate-specific membrane antigen (psma) imaging biomarkers for aggressive prostate cancer

H Al Saffar, DC Chen, C Delgado, J Ingvar, MS Hofman… - Cancers, 2024 - mdpi.com
Simple Summary The review explores the critical role of prostate-specific membrane antigen
(PSMA) PET/CT imaging in diagnosing, staging, and treating prostate cancer. PSMA PET/CT …

Role of bromodomain and extraterminal (BET) proteins in prostate cancer

A Mandl, MC Markowski, MA Carducci… - Expert opinion on …, 2023 - Taylor & Francis
Introduction The bromodomain and extraterminal (BET) family of proteins are epigenetic
readers of acetylated histones and are critical activators of oncogenic networks across many …

Current status of PSMA-targeted radioligand therapy in the era of radiopharmaceutical therapy acquiring marketing authorization

SW Oh, M Suh, GJ Cheon - Nuclear Medicine and Molecular Imaging, 2022 - Springer
Prostate-specific membrane antigen (PSMA) is highly expressed in PCa, which gradually
increases in high-grade tumors, metastatic tumors, and tumors nonresponsive to androgen …

Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer

E Murce, S Beekman, E Spaan, M Handula… - Molecules, 2023 - mdpi.com
Prostate-specific membrane antigen (PSMA) targeting radiopharmaceuticals have been
successfully used for diagnosis and therapy of prostate cancer. Optimization of the available …

Normal variants, pitfalls, and artifacts in Ga-68 prostate specific membrane antigen (PSMA) PET/CT imaging

N Malan, MT Vangu - Frontiers in Nuclear Medicine, 2022 - frontiersin.org
The advent of gallium 68 prostate specific membrane antigen (PSMA) PET imaging has
revolutionized the diagnosis and treatment of prostate cancer. PSMA is a transmembrane …